09:05:03 EDT Fri 23 Aug 2019
Enter Symbol
or Name

Login ID:
Shell Summary
Symbol C : *MKTSHEL
Recent Sedar Documents

Shell Summary for Jan. 25, 2019

2019-01-25 20:36 ET - Market Summary

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The TSX Venture Exchange climbed 11.18 points to 604.56 Friday, ending the week up 9.05 points. Stephen Shefsky's first capital pool shell, BB1 Acquisition Corp. (BBA: halted), plans to acquire an Israeli pharmaceutical marijuana company, Plantext Ltd., for the shell's qualifying transaction. The shell will roll back 1 for 7.15, leaving it with 2.25 million shares issued, then issue 23,052,116 shares to its target's shareholders.

Plantext was formed in 2015. It has a research and development lab near Tel Aviv and is working on marijuana-based treatments for inflammatory diseases. Specifically, its R&D efforts involve marijuana oil extracts. The company is co-developing an over-the-counter drug for treating inflammatory bowel disease (IBD) with Israel's Agricultural Research Organization (ARO). Plantext and ARO aim to release their IBD treatment in Israel later this quarter.

Plantext is also developing some products on its own. It hopes to release in the second quarter a cream for treating psoriasis. It also hopes to release in the same quarter a line of pain-treatment products in the forms of a tincture, a topical cream and a gel capsule.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2019 Canjex Publishing Ltd. All rights reserved.

Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.